For Chronic Lymphocytic Leukemia (CLL) with a chromosome 17 mutation and deletion of TP53, ibrutinib is the preferred first-line treatment if a clinical trial is unavailable. If a second round of treatment is needed, options include:

- Ibrutinib
- Venetoclax with rituximab
- Idelalisib
- Duvelisib

These treatments are Show Full Answer

For Chronic Lymphocytic Leukemia (CLL) with a chromosome 17 mutation and deletion of TP53, ibrutinib is the preferred first-line treatment if a clinical trial is unavailable. If a second round of treatment is needed, options include:

- Ibrutinib
- Venetoclax with rituximab
- Idelalisib
- Duvelisib

These treatments are recommended due to their effectiveness in managing CLL with these specific genetic markers.

 This AI-generated response comes from MyLeukemiaTeam and other selected sources. It is not a substitute for medical advice. Always ask your doctor about specific health concerns.

Chronic Lymphocytic Leukemia Treatment Options | MyLeukemiaTeam

What Is CLL? Prevalence, Prognosis, Treatment, and More | MyLeukemiaTeam